News Hub

Aug 5, 2026

Sofia Navarro

Press Releases

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020, its investigational gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy. This designation, along with prior Orphan Drug and Fast Track statuses, highlights promising interim clinical data from the ongoing Phase I/II HEROIC-PKP2…

LXEO

Aug 5, 2026

Derek Hwang

Press Releases

Advantage Solutions Reports Second Quarter 2026 Results

Advantage Solutions Inc. reported Q2 2026 revenues of $889.5 million, a 1.8% increase year-over-year, driven primarily by growth in Experiential Services and slight growth in Retailer Services while Branded Services declined. Despite higher revenue, net loss widened to $62.7 million and Adjusted EBITDA dropped 12.2% to $75.8 million. The company re…

ADV

Aug 5, 2026

Maya Rios

Press Releases

TeraWulf Reports Second Quarter 2026 Results

TeraWulf reported second quarter 2026 results highlighting revenue growth with 102 MW of revenue-generating capacity at Lake Mariner and 336 MW under construction. The company secured a landmark 20-year, approximately $19 billion lease with Anthropic at its Kentucky Justified Data Campus and acquired the gigawatt-scale Muskie Data Campus. TeraWulf …

WULF

Aug 5, 2026

Hana Yamamoto

Press Releases

Astec Reports Second Quarter 2026 Results

Astec Industries, Inc. reported its second quarter 2026 financial results with net sales rising 23.6% to $408.1 million and backlog increasing nearly 58%. Despite growth in Materials Solutions, delays in Infrastructure Solutions asphalt plant shipments caused a reduction in full-year adjusted EBITDA guidance from $170-$190 million to $160-$175 mill…

ASTE

Aug 5, 2026

Nina Shah

Press Releases

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Atea Pharmaceuticals, a late-stage biopharmaceutical company developing oral antivirals for serious viral diseases, announced its Q2 2026 financial results call scheduled for August 12, 2026. The company continues to progress its Phase 3 hepatitis C program and Phase 1 hepatitis E study, sharing updates with investors.

AVIR

Aug 5, 2026

Avery Klein

Press Releases

Telix to Host R&D Day in New York City on September 22, 2026

Telix Pharmaceuticals Limited will host an R&D Day event in New York City on September 22, 2026, providing investors and analysts with a comprehensive update on its therapeutic and precision medicine pipeline. The event will feature presentations from company leadership and key opinion leaders, highlighting clinical, scientific, and strategic devel…

TLX

Aug 5, 2026

Nina Shah

Press Releases

Hennessy Capital Investment Corp. VII and ONE Nuclear Energy LLC Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination

Hennessy Capital Investment Corp. VII (NASDAQ: HVII) and ONE Nuclear Energy LLC announced that the SEC has declared effective their registration statement, enabling a shareholder meeting on August 24, 2026, to approve their proposed business combination. Upon closing, ONE Nuclear Energy Inc. will become a publicly traded company on NASDAQ under the…

ONEN

Aug 5, 2026

Nina Shah

Press Releases

J & J Snack Foods Reports Fiscal 2026 Third Quarter Results

J & J Snack Foods Corp. reported its fiscal 2026 third quarter results with a 6.2% decline in net sales to $426 million, impacted mainly by reduced bakery and frozen beverage machine sales. Despite lower sales, gross profit rose slightly and gross margin expanded by 240 basis points to 35.5%, attributed to operational efficiencies under the Apollo …

JJSF

Aug 5, 2026

Nina Shah

Press Releases

Royalty Pharma reports second quarter 2026 results

Royalty Pharma plc announced robust second quarter 2026 results with 14% growth in Royalty Receipts to $768 million and an overall 6% increase in Portfolio Receipts to $773 million. The company raised its full-year 2026 portfolio receipts guidance to $3.4 to $3.5 billion driven by strong performance of key products and active investments in new roy…

RPRX

Aug 5, 2026

Sofia Navarro

Press Releases

Kaltura Announces Financial Results for Second Quarter 2026

Kaltura, Inc. announced strong second quarter 2026 results, surpassing revenue and adjusted EBITDA guidance. Subscription revenue grew 8% year-over-year to $45.6 million, with total revenue at $46.9 million. The company achieved record non-GAAP gross margin of 75% and its highest Q2 adjusted EBITDA to date at $5.9 million. Kaltura signed a record f…

KLTR

Aug 5, 2026

Caleb Monroe

Press Releases

Climb Signs Distribution Agreement with Harmonic Security to Help Secure Mid-Market & Enterprise AI Adoption

Climb Global Solutions, Inc., a U.S.-based technology distributor, announced a distribution partnership with Harmonic Security to offer its AI governance platform to value-added resellers and managed service providers. This collaboration targets enhanced security for mid-market and enterprise adoption of AI, addressing risks from autonomous AI agen…

CLMB

Aug 5, 2026

Ajmal Hussain

Press Releases

VisionWave Expands AI Defense Platform with Planned Acquisition of Perimeter Security Provider D-Fence

VisionWave Holdings, Inc. announced a planned acquisition of at least 51% of D-Fence Electronic Fencing Systems Ltd., an Israeli developer of AI-driven perimeter security technologies used in critical infrastructure worldwide. The transaction aims to build a comprehensive AI-powered defense platform by integrating D-Fence's solutions with VisionWav…

VWAV

Aug 5, 2026

Priya Menon

Press Releases

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma reported positive regulatory milestones, including a favorable CHMP opinion recommending marketing authorization for obicetrapib and its fixed-dose combination with ezetimibe in Europe. The company provided updates on ongoing Phase 3 cardiovascular and Alzheimer's disease trials, announced cash position of $678.3 million as of J…

NAMS

Aug 5, 2026

Ajmal Hussain

Press Releases

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Pharmaceuticals reported robust Q2 2026 financial results with total net revenue of $218.3 million, an operating profit of $98.5 million, and maintained full-year ORLADEYO revenue guidance while raising total revenue outlook. Key milestones include starting shipments of ORLADEYO oral pellets for pediatric hereditary angioedema patients and…

BCRX

Aug 5, 2026

Maya Rios

Press Releases

Ascent Solar Technologies Meets Growing Drone Market Demand; Reinforces Primary Space Industry Focus

Ascent Solar Technologies highlights its growing involvement in the expanding drone market alongside its core space industry applications. The company secured orders from satellite manufacturers and unmanned aerial and marine vehicle producers, showcasing its innovative thin-film photovoltaic technology that offers a superior power-to-weight ratio.…

ASTI

Aug 5, 2026

Nina Shah

Press Releases

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics reported Q2 2026 financial results highlighting rapid enrollment completion of their KT-621 Phase 2b trial in atopic dermatitis ahead of schedule, with topline data expected by year-end 2026. The company plans to initiate Phase 3 trials in mid-2027 and reported ongoing progress in multiple clinical programs addressing immunologi…

KYMR

Aug 5, 2026

Derek Hwang

Press Releases

Sprott Announces Second Quarter 2026 Results

Sprott Inc. announced its Q2 2026 results with Assets Under Management (AUM) declining 15% from Q1 due to corrections in gold and silver prices. Despite this, average AUM grew 70% year over year, driven by strong inflows and market appreciation in critical materials products. Management fees increased by 72% year over year, while net income rose to…

SII

Aug 5, 2026

Hana Yamamoto

Press Releases

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation reported an 11% increase in net product revenue for its RYTELO (imetelstat) drug in Q2 2026 compared to Q1, reaching $57.5 million. The company reaffirmed its 2026 financial guidance, expecting RYTELO net product revenues between $220 million and $240 million. Geron expanded its leadership team, presented positive real-world effic…

GERN

Aug 5, 2026

Avery Klein

Press Releases

Factorial to Attend Upcoming Investor Conferences

Factorial Energy Inc., a US-based innovator in solid-state battery technology, announced its plans to attend the Oppenheimer Technology, Internet & Communications Conference and the J.P. Morgan Auto Conference in August 2026. The company highlighted its proprietary battery platforms backed by prominent industry and strategic investors and recent pe…

FAC

Aug 5, 2026

Maya Rios

Press Releases

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Entrada Therapeutics reported its second quarter 2026 financial results, highlighting strong progression in its clinical pipeline targeting neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Key clinical data readouts for their ENTR-601 program cohorts are expected between late 2026 and early 2027, al…

TRDA

Aug 5, 2026

Hana Yamamoto

Press Releases

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Seres Therapeutics announced second quarter 2026 financial results highlighting a net income of $4.6 million, driven by a $25 million milestone payment from Nestlé for the VOWST business sale. The company reported encouraging investigator-sponsored trial results for SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), showing 80% of…

MCRB

Aug 5, 2026

Nina Shah

Press Releases

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics reported Q2 2026 financial results and business updates, highlighting the initiation of two Phase 3 trials (FOCUS 1 and FOCUS 2) for RAP-219 in focal onset seizures. The company remains on track for topline Phase 2 results in bipolar mania later in 2026 and is progressing other pipeline candidates including a long-acting inject…

RAPP

Aug 5, 2026

Hana Yamamoto

Press Releases

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

Tonix Pharmaceuticals, a commercial-stage biotech company focusing on CNS disorders, infectious diseases, immunology, and rare diseases, announced their upcoming participation in two investor conferences. Leadership will present company progress and pipeline developments, including marketed products TONMYA® for fibromyalgia and acute migraine treat…

TNXP

Aug 5, 2026

Hana Yamamoto

Press Releases

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies and treatment for rare and serious conditions, announced it will release its second quarter and first half 2026 financial results on August 12, 2026, before U.S. markets open. The company will host a conference call to discuss results and provide upda…

KMDA

Aug 5, 2026

Derek Hwang

Press Releases

GlobalFoundries Reports Second Quarter 2026 Financial Results

GLOBALFOUNDRIES Inc. announced its preliminary Q2 2026 financial results, reporting revenue of $1.786 billion, surpassing guidance. The company demonstrated strong margin expansion and net income, driven by growing demand in AI data center solutions, semiconductor technology innovation, and strategic acquisitions. GF secured a $300 million governme…

GFS